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1. Introduction 
Cholera toxin, the diarrheogenic protein of Vibrio 
cholerae, has a mol. wt of 84 000 and is composed of 
subunits of two types, L and H [1-3].  Both subunits 
are required for biologic activity but only the L type 
is involved in the high-affinity binding of toxin to the 
cell surface [1-4].  Recent chemical modification 
analyses have further elucidated the different functional 
sites of the toxin [5]. 
A specific ganglioside, GM1 , has been identified as 
the binding membrane receptor for cholera toxin in 
intestinal as well as non-intestinal mammalian cells 
[6-9].  Cell-binding of the toxin is followed by 
activation of adenylate cyclase which causes various 
effects in different cell types [10-12]. The activating 
'signal' for adenylate cyclase is unknown. Unlike e.g. 
the stimulation of this enzyme by epinephrine there is 
a characteristic 'lag' period in the toxin action [10-12] 
In the present study we describe for the first time 
inhibition of cell adenylate cyclase stimulation by 
cholera toxin which is associated with unchanged 
cell-binding of the toxin and unimpaired cyclase 
response to epinephrine and prostaglandin'. We 
propose to have interfered with a cell component 
required to translate the initial toxin - GM1 receptor 
binding into an adenylate cyclase activating signal. 
2. Materials and methods 
2.1. Materials 
Isolated cholera toxin was prepared by R. A. 
Finkelstein, Dallas, Texas [13]. Radiolabelling of the 
toxin with 12 s I was done as described [4]. Prostaglandin 
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E1 (PGE1) was generously donated by Dr John Pike, 
the Upjohn Co. Epinephrine, 1-ethyl-3(3-dimethyl- 
aminopropyl) carbodiimide (EDC), glycine-O-methyl 
ester, N-ethylmaleimide, picryl sulfonic acid and 
succinic anhydride was from Sigma, N-cyclohexyl-3 
(2-morpholinoethyl) carbodiimide meto-p-toluene- 
sulfonate (CMC) from EGA-Chemie KG, (Steinheim/ 
Albuch, W. Germany), N,N'-dicyclohexyl carbodiimide 
(DCC) from Merck, and Medium RPMI 1640 and foetal 
calf serum (FCS) from Flow Laboratories. 
2.2. Incubation of  cells and determination f cyclic 
3'5'-adenosine monophosphate 
Thymus lymphocytes from CBA mice were prepared 
as previously described [4] and the cells suspended in
the medium used. 107 cells were incubated with 10 -9 M 
cholera toxin, 10 -6 M epinephrine or 10 -4 M PGE1 at 
37°C in 1 ml RPMI 1640 containing 10% FCS (RPMI- 
FCS). The cells were harvested by centrifugation a d 
cyclic 3'5'-adenosine monophosphate (cAMP) extracted 
and assayed essentially as described by Bourne et al. 
[14]. The values reported are those after correction for 
losses during isolation and varied by less than 10 per 
cent in duplicate determinations. 
2.3. Chemical modification of  cells 
Treatment of thymocytes with group modifying 
chemicals or other substances was performed for 
30 minutes, usually at 37°C, using 107 cells per ml 
RPMI-FCS medium or phosphate-buffered saline. 
Thereafter the modified cells were washed twice by 
centrifugation (700 g, lmin) in phosphate-buffered 
saline and subjected to toxin or hormone stimulation 
as described above. 
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2.4. Binding of radioiodinated cholera toxin to cells 
Binding of cholera toxin to cells was tested using 
radioiodinated toxin in mixture with various concentra 
tions of unlabelled toxin according to a previously 
described procedure [4]. 
3. Results 
3.1. Modified cells stimulated by cholera toxin or 
hormones 
Thymocytes suspended in RPMI-FCS medium were 
pretreated with eight modifying reagents (table 1). 
ffter washing, the cells were resuspended in fresh 
RPMI-FCS medium and incubated with cholera toxin, 
epinephrine or PGEx. 
Amino group specific ell modification with picryl 
sulfonic acid or succinic anhydride had no pronounced 
influence on the cAMP response to cholera toxin. 
Carboxyl group specific ell modification was 
performed with three carbodiimides, EDC and CMC 
which both are water-soluble and DCC which is only 
sparsely water-soluble. EDC had a differential effect 
on cellular cAMP response to cholera toxin on one 
hand and epinephrine and PGEI on the other (table 1). 
The toxin response was strongly inhibited (88-95 
per cent in six different experiments). The cAMP 
response to the hormones was instead slightly 
enhanced. When the nucleophilic reagent glycine-O- 
methyl ester was added to EDC the inhibitory effect 
on the response to cholera toxin was diminished and 
the enhancement of the epinephrine stimulation was 
amplified. By itself glycine-O-methyl ester was slightly 
inhibitory for either system. Of the other carbodiimide~ 
CMC weakly and DCC strongly inhibited cellular 
responsiveness to both toxin and epinephrine. 
A nondiscriminate inhibitory effect on the response 
to cholera toxin and epinephrine was observed by 
treating the cells with the alkylating reagent ethyl- 
maleimide. 
3.2. Binding of cholera toxin to modified cells 
The possibility that EDC affected the GMI 
ganglioside cell receptor for cholera toxin, was investigat- 
ed. As shown in fig.1 there was no significant 
difference between untreated and EDC-modified cells 
in their binding of 12 s I-labelled toxin. 
3.3. Bicarbonate requirement of EDC 
Since the cAMP stimulating ability of cholera toxin 
was selectively affected by EDC, the cell modifying 
ability of this reagent was investigated more closely. 
When pretreatment of cells with EDC was performed 
in phosphate-buffered saline instead of the RPMI-FCS 
tissue culture medium, the inhibitory action disappear- 
ed (table 2). Different components of the RPMI-FCS 
Table 1 
Specific inhibition of cAMP response to cholera toxin by cell modification with EDC a 
Picomoles cAMP/10 T cells in response to, 
Cell modifying chemical Cholera Epinephrine PGE~ No addi- 
toxin five 
None 300 122 340 6 
Picryl sulfonic acid (1 mM) 400 6 
Succinic anhydride (1 mM) 400 6 
EDC (1 mM) 34 196 389 6 
EDC (1 raM) + Glycine-O-methyl ester (5 mM) 170 332 6 
Glycine-O-methyl ester (5 mM) 146 90 6 
CMC (1 mM) 156 80 5 
DCC (0.1 raM) 3 2 3 
Sodium cyanide (1 mM) 6 6 6 
Ethyl maleimide (1 mM) 3 3 3 
a l0 T thymocytes in 1 ml RPMI-FCS medium were treated with modifying chemicals and then 
washed. Thereafter the modified cells were suspended in fresh medium and incubated at 37°C 
with cholera toxin (10 -9 M, 50 rain), ¢pinephrh~ (10 -6 M, 25 min), prostaglandin E l (PGEt ; 
10 -a M, 15 min) or with no stimulant (50 min). Intracellular cAMP was then determined. 
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Fig.1. Binding of  cholera toxin to untreated cells (open 
columns) and cells treated with 1 mM EDC (hatched columns) 
as tested using radiolabelled toxin in mixtures with various 
concentrations of unlabelled toxin. The means -+ 2 SD are 
indicated. 
medium like amino acids, vitamins, glucose and salts 
were investigated for a presumptive synergism with 
EDC in the inhibition of the cell response to cholera 
toxin. It was found that the only component which 
was able to restore the inhibitory action of EDC was 
sodium bicarbonate. Other salts of carbonic acids 
tried were ineffective as seen in table 2. 
3.4. EDC &hibition in relation to time and temperature 
When pretreatment of cells with EDC in RPMI-FCS 
medium was performed at different emperatures, the 
inhibitory effect on cholera toxin induction of cAMP 
was found to be highly temperature d pendant (fig.2a). 
At 37°C the inhibition was almost complete, at 23°C 
slight and at 0°C nil. 
Cholera toxin has in all cell types a characteristic 
lag period between binding and cAMP accumulation 
[10-12], which in thymus cells is 15-30 min [15]. 
In order to relate the kinetics of the cellular effect of 
cholera toxin with the inhibition of this effect by EDC, 
cells were incubated with the toxin for 50 min. EDC 
(lmM) was supplied at 0, 5, 15, 30 and 50 min of this 
Table 2 
Requirement of  bicarbonate for the inhibitory 
activity of  EDC a 
Cell modifying chemical Picomoles cAMP/107 cells in 
response to cholera toxin 
None 280 
EDC alone 250 













a 107 thymocytes in 1 ml phosphate-buffered saline were 
pretreated with 1 mM EDC together with 10 mM concentra- 
tions of  various acids (added as sodium salts) or divalent ions 
(added as chloride salts). The modified cells were then 
suspended in fresh RPMI-FCS medium and incubated with 
cholera toxin (10 -9 M, 37°C, 50 min) and intracellular 








0'~ 2~°c ' 37°C 
temperature  of  mod i f i ca t ion  
/i 
minutes  between tox in  and EDC add i t ion  
Fig.2. Effect of  EDCon cAMP response to cholera toxin in 
relation to temperature of cell modification (a) or time 
interval between cell exposure to toxin and reagent (b). (a) 
107 thymocytes in 1 ml RPMI-FCS medium were incubated 
at 0, 23 or 37°C for 30 min with (e - -e )  or without (o - -o )  
1 mM EDC. Then the treated cells were washed twice, supplied 
with fresh medium and incubated with 10 -9 M cholera toxin 
at 37°C for 50 min. Thereafter intracellular cAMP was 
determined. (b) Samples with 107 thymocytes were incubated 
at 37°C for 50 min in 1 ml RPMI-FCS medium containing 
10 -9 M cholera toxin. At various times during this incubation 
1 mM EDC was added. Intracellular cAMP was determined after 
completion of the incubation. 
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incubation. Fig.2b shows that the inhibitor was still 
effective when supplied 5 minutes after the toxin but 
not after 30 or 50 min. Thus, EDC inhibits the cellular 
cAMP response to cholera toxin provided that it is 
applied early in the toxin's own lag period. 
4. Discussion 
.: Cholera toxin and several hormones including 
epinephrine stimulate cells in a somewhat similar manner. 
After an initial binding of the agents to specific cell 
membrane receptors adenylate cyclase is activated, in 
the case of toxin stimulation with a typical 'lag' period. 
The ensuing cAMP formation thereafter via specific 
protein kinases influences various cellular processes. 
The binding of cholera toxin to cell membrane GM1 
ganglioside receptors takes place within a few minutes 
[4,16]. The significant delay between binding and 
activation of adenylate cyclase has suggested that inter- 
mediary processes are required to translate the initial 
binding event into an activating signal. The present 
study was undertaken i an approach to recognize by 
interference with its function, a possible membrane 
component of importance for such an intermediary 
signal. 
The fat-soluble carbodlimide DCC has been described 
to inhibit several cell metabolic processes [ 17-19]. In 
our systems DCC inhibited adenylate cyclase stimulation 
by cholera toxin as well as epinephrine, i.e. it did not 
interfere with a signal unique for the toxin. A specific 
inhibition of toxin-induced cAMP was, however, obtain- 
ed by treatment of cells with EDC, another carbodiimide, 
in the presence of bicarbonate. The basic levels of cAMP 
were unchanged and the cAMP response to epinephrine 
as well as to prostaglandin E1 slightly potentiated by 
the treatment indicating that the cyclase nzyme was 
not inhibited. Further, the binding of cholera toxin to 
the cell surface was unchanged by the treatment 
indicating intact binding activity of the GM1 ganglioside 
receptors. The requirement of bicarbonate for the 
inhibitory action of EDC is as yet unexplained. 
Possibly bicarbonate reacts with the carbodiimide to 
form an unstable derivative with enhanced membrane 
permeability or altered specificity. 
The pronounced temperature d pendence of the 
inhibitory activity of EDC-bicarbonate might suggest 
that a 'fluid-penetrable' c ll membrane is required 
to enable contact between the reagent and the site 
which is modified. Since the inhibition was evident only 
during the lag period of the toxin action the EDC- 
bicarbonate treatment probably affects a membrane 
structure involved in translating the toxin binding into 
an adenylate cyclase activating signal. The interpreta- 
tion of the presented ata is compatible with a 
proposed scheme of interactions of cholera toxin 
subunits with cell membrane structures [4]. According 
to this model the initial binding of the toxin by L 
subunit o GM1 receptors opens up a previously hidden 
membrane structure with which the toxin H subunit 
can interact. The resulting modulation of this mem- 
brane component then leads to activation of adenylate 
cyclase, either directly via a mechanical configurational 
change or indirectly via intermediary messengers. 
To summarize, we claim to have blocked a cholera 
toxin specific 'signal' required for activation of 
adenylate cyclase in thymus cells and propose that this 
inhibition was due to a chemical modification of a 
membrane component functionally bridging the GM1 
ganglioside receptors with adenylate cyclase. In addition 
to the implications for understanding the mechanism 
of action of cholera toxin and of adenylate cyclase 
activation, the study suggests a possible level for 
specific prophylactic-therapeutic interference with 
cholera disease. 
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